Allstocks.com's Bulletin Board Post A Reply
my profile login | register | search | faq | forum home

» Allstocks.com's Bulletin Board » NASDAQ, AMEX, NYSE Stocks » ISR IsoRay » Post A Reply

Post A Reply
Login Name:
Password:
Message Icon: Icon 1     Icon 2     Icon 3     Icon 4     Icon 5     Icon 6     Icon 7    
Icon 8     Icon 9     Icon 10     Icon 11     Icon 12     Icon 13     Icon 14    
Message:

HTML is not enabled.
UBB Code™ is enabled.

 

Instant Graemlins Instant UBB Code™
Smile   Frown   Embarrassed   Big Grin   Wink   Razz  
Cool   Roll Eyes   Mad   Eek!   Confused   BadOne  
Good Luck   More Crap   Wall Bang   Were Up   Were Down    
Insert URL Hyperlink - UBB Code™   Insert Email Address - UBB Code™
Bold - UBB Code™   Italics - UBB Code™
Quote - UBB Code™   Code Tag - UBB Code™
List Start - UBB Code™   List Item - UBB Code™
List End - UBB Code™   Image - UBB Code™

What is UBB Code™?
Options


Disable Graemlins in this post.


 


T O P I C     R E V I E W
BooDog  - posted
Read more: http://www.nasdaq.com/symbol/isr#ixzz2xTSn5eJm
ISR $2.63

Share Statistics
Avg Vol (3 month)3: 6,387,060
Avg Vol (10 day)3: 38,413,000
Shares Outstanding5: 38.41M
Float: 37.92M
% Held by Insiders1: 1.89%
% Held by Institutions1: 2.90%
Shares Short (as of Mar 14, 2014)3: 2.28M
Short Ratio (as of Mar 14, 2014)3: 1.70
Short % of Float (as of Mar 14, 2014)3: 6.10%
Shares Short (prior month)3: 1.70M


IsoRay Medical™ utilizes proprietary technologies to deliver novel brachytherapy approaches to clinicians. IsoRay's Cesium-131 isotope has been used as primary treatment for prostate cancer in over 7,000 patients. As adjuvant radiation therapy, Cesium-131 is being employed in the management of non-small cell lung cancer, intra-cranial tumors (including meningiomas), and head & neck malignancies post-surgical resection.

Additionally, Cesium-131 is currently being used as monotherapy in the management of gynecologic recurrences and ocular melanomas Customized strands, meshes, and applicators are available bearing Cesium-131 sources, and the recently reintroduced GliaSite Radiation Therapy System is available for brachytherapy of the resection bed following surgical removal of gliomas and brain metastases.


http://www.isoray.com/

•IsoRay, Inc. Closes $14,675,180 Registered Direct Offering March 27, 2014
•IsoRay Prices Registered Direct Offering of Common Stock March 21, 2014
•IsoRay Announces Greek Governmental Approval for Sales of It’s Entire Product Line March 11, 2014
•IsoRay, Inc Reports Second Quarter Results February 18, 2014
•IsoRay Receives Five Year CE Mark Extension for All Cesium-131 Seed Products January 29, 2014

2014 Events just for April...

ABS
American Brachytherapy Society
2014 ABS Annual Meeting
April 3th – April 5th, 2014
Manchester Grand Hyatt
San Diego, CA
Visit us at booth 301

AANS
American Association of Neuro Surgeons
2014 82nd AANS Annual Scientific Meeting
April 7th – April 9th, 2014
Moscone Center
San Francisco, CA

AATS
American Association for Thoracic Surgery
2014 AATS 94th Annual Meeting
April 26th – April 30th, 2014
Toronto, Canada
 
BooDog  - posted
HOD 3.14, riding free.

[Were Up] [Were Up]
 
BooDog  - posted
Day's Range 2.85 - 3.47

mighta settled down a bit. Still keeping some freebies.
 
BooDog  - posted
IsoRay Has Tremendous Potential Gaining More Published Peer Reviews

http://finance.yahoo.com/news/isoray-tremendous-potential-gaining-more-164000939 .html

This is exactly what I have been hitting on for the last couple weeks.
I see there's some consensus at least. smile


When it comes to emerging companies like IsoRay one major obstacle though is funding. But here again, IsoRay is in a solid position. Babcock told us that the company has around $20 million in cash on its balance sheet, which at the current burn rate is sufficient to last for eight years. When asked whether the company will look to capitalize on the surge in share price this year by coming out with a secondary offering, Babcock said that there is no immediate need for such an offering. However, he added that the company would always like to be in a strong cash position, especially if it considers a synergistic acquisition in the future.

Now isn't THAT an interesting statement. smile
 



Contact Us | Allstocks.com Message Board Home

© 1997 - 2013 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share